
CCRN Stock Forecast & Price Target
CCRN Analyst Ratings
Bulls say
Cross Country Healthcare has demonstrated a stabilization in gross margins at 20.0%, consistent with the previous quarter and surpassing estimates, indicating operational resilience. Additionally, the pending acquisition by Aya Healthcare at $18.61 per share represents a substantial 67% premium over the stock's closing price prior to the announcement, reflecting strong market confidence in the company's value. Furthermore, the anticipated timeline for the transaction's completion shifts to the second half of 2025, allowing for strategic positioning amid evolving market conditions.
Bears say
Cross Country Healthcare reported a significant decline in Adjusted EBITDA, dropping 44% year-over-year to $8.6 million in Q1/25, despite exceeding internal estimates. The company also experienced a revenue decline of 23% year-over-year to $293.4 million, which fell short of both internal and consensus estimates, reflecting ongoing softer demand in the healthcare travel staffing sector. Following these results, the revenue forecast for 2025 was revised downward to $1.166 billion, representing a decrease of 13.3% year-over-year from prior projections.
This aggregate rating is based on analysts' research of Cross Country Healthcare and is not a guaranteed prediction by Public.com or investment advice.
CCRN Analyst Forecast & Price Prediction
Start investing in CCRN
Order type
Buy in
Order amount
Est. shares
0 shares